Xencor Inc
NASDAQ:XNCR

Watchlist Manager
Xencor Inc Logo
Xencor Inc
NASDAQ:XNCR
Watchlist
Price: 17.06 USD -0.58% Market Closed
Market Cap: 1.2B USD

Wall Street
Price Targets

XNCR Price Targets Summary
Xencor Inc

Wall Street analysts forecast XNCR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for XNCR is 28.56 USD with a low forecast of 17.17 USD and a high forecast of 44.1 USD.

Lowest
Price Target
17.17 USD
1% Upside
Average
Price Target
28.56 USD
67% Upside
Highest
Price Target
44.1 USD
158% Upside
Xencor Inc Competitors:
Price Targets
301047
Sino Biological Inc
17% Upside
BBIO
BridgeBio Pharma Inc
15% Upside
PHM
Pharma Mar SA
32% Upside
301207
Hualan Biological Bacterin Inc
3% Downside
SCLP
Scancell Holdings PLC
219% Upside
6855
Ascentage Pharma Group International
80% Upside
ATRA
Atara Biotherapeutics Inc
3% Downside
NRIX
Nurix Therapeutics Inc
45% Upside

Revenue
Forecast

Revenue Estimate
Xencor Inc

For the last 12 years the compound annual growth rate for Xencor Inc's revenue is 23%. The projected CAGR for the next 3 years is 7%.

23%
Past Growth
7%
Estimated Growth
Estimates Accuracy
19%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Xencor Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-16%
Average Miss

Net Income
Forecast

Net Income Estimate
Xencor Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-32%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is XNCR's stock price target?
Price Target
28.56 USD

According to Wall Street analysts, the average 1-year price target for XNCR is 28.56 USD with a low forecast of 17.17 USD and a high forecast of 44.1 USD.

What is Xencor Inc's Revenue forecast?
Projected CAGR
7%

For the last 12 years the compound annual growth rate for Xencor Inc's revenue is 23%. The projected CAGR for the next 3 years is 7%.

Back to Top